ガンシクロビルの世界市場レポート 2025年

ガンシクロビル市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.5%で22億米ドルに成長します。この予測期間における成長は、抗ウイルス療法の採用拡大、免疫不全状態の有病率の上昇、CMV感染に対する認知度の向上、診断技術の進歩、新興市場におけるヘルスケアインフラの拡大などに起因しています。予測期間中に予想される主な動向としては、ドラッグデリバリー法の革新、徐放性製剤の創出、併用療法の進歩、CMV早期発見のための高度診断ツールの使用、CMV感染症の個別化治療戦略の出現などが挙げられます。

サイトメガロウイルス（CMV）感染症の罹患率の増加は、今後数年間のガンシクロビル市場の成長を促進すると予想されます。一般的なヘルペスウイルスによって引き起こされるCMV感染症は、免疫力が低下している人では潜伏したまま再活性化し、網膜炎、肺炎、胃腸障害などの重篤な合併症を引き起こす可能性があります。CMV感染者の増加は、免疫不全者の増加によるところが大きく、免疫防御機能が低下しているため、ウイルスの再活性化や感染に対する脆弱性が高まっています。ガンシクロビルは、効果的な抗ウイルス治療を提供する上で重要な役割を担っており、リスクのある人々の間で増加するCMV感染率を管理する上で重要であることを強調しています。例えば、2025年1月、米国の公衆衛生機関である疾病対策予防センター（CDC）は、米国の小児の3人に1人が5歳までにCMVに感染し、成人の半数以上が40歳までに感染すると報告しました。さらに2022年10月、米国の医療機関である国立医学図書館は、毎年約4万人の乳児が先天性CMV（cCMV）に感染して生まれ、そのうち約400人（1％）が感染により死亡し、約8,000人（25％）が長期合併症に苦しんでいると指摘しました。このように、CMV感染症の増加がガンシクロビル市場の拡大に寄与しています。

ヘルスケア支出の増加は、ガンシクロビル市場の今後の成長を牽引すると予想されます。ヘルスケア支出とは、個人、保険業者、政府による医療サービス、治療、公衆衛生への総支出を指します。この支出の増加は、医療技術の進歩によるところが大きいが、これらの技術には高額な開発・導入コストがかかることが多く、専門的な機器やトレーニングが必要で、高額な診断・治療手技への依存度が高まる。ヘルスケア支出の増加は、特に免疫不全者のサイトメガロウイルス（CMV）感染を管理するための抗ウイルス治療へのアクセスを拡大することにより、ガンシクロビルの使用を促進します。例えば、2024年5月、英国の政府機関であるOffice for National Statisticsは、2024年の同国のヘルスケア支出が約4,213億2,000万米ドル（3,170億英ポンド）に達し、2023年から6.5％増加したと報告しました。このように、ヘルスケア支出の拡大がガンシクロビル市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のガンシクロビル：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のガンシクロビル市場：成長率分析
• 世界のガンシクロビル市場の実績：規模と成長、2019年～2024年
• 世界のガンシクロビル市場の予測：規模と成長、2024年～2029年、2034年
• 世界のガンシクロビル：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のガンシクロビル市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 注射
• 経口
• 世界のガンシクロビル市場：剤形別、実績と予測、2019年～2024年、2024年～2029年、2034年
• タブレット
• 静脈内（IV）溶液
• 点眼ジェル
• 世界のガンシクロビル市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のガンシクロビル市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• サイトメガロウイルス（CMV）網膜炎
• 臓器移植患者におけるサイトメガロウイルス（CMV）予防
• その他の用途
• 世界のガンシクロビル市場、注射のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 注射用凍結乾燥粉末
• プレミックスIVバッグ
• 硝子体内注射
• 世界のガンシクロビル市場、経口のサブセグメンテーション、タイプによるサブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• カプセル
• 経口溶液

第7章 地域別・国別分析

• 世界のガンシクロビル市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のガンシクロビル市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ガンシクロビル市場：競合情勢
• ガンシクロビル市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fareva Group
• Zydus Lifesciences Ltd.
• Natco Pharma Ltd.
• Ajanta Pharma Ltd.
• Micro Labs Ltd.
• Taj Pharmaceuticals Ltd.
• Sunways Pvt. Ltd.
• Accord Healthcare Ltd.
• AdvaCare Pharma USA
• Trifarma S.p.A.
• Actiza Pharmaceutical Pvt. Ltd.
• Bakul Group of Companies
• Doctor Wonder Healthcare Pvt. Ltd.
• Sujalam Chemicals
• Aetos Pharma Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ガンシクロビル市場2029年：新たな機会を提供する国
• ガンシクロビル市場2029年：新たな機会を提供するセグメント
• ガンシクロビル市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ganciclovir is a man-made antiviral drug used to treat cytomegalovirus (CMV) infections, especially in individuals with weakened immune systems, such as those with HIV/AIDS or organ transplant recipients. As a nucleoside analogue, it works by blocking viral DNA synthesis, thereby stopping the replication of CMV. This aids in controlling the viral load and lowers the risk of disease progression.

Ganciclovir is primarily available in two forms: injection and oral. The injectable version is administered intravenously and is mainly used to treat or prevent CMV infections in immunocompromised patients. It comes in different dosage forms, including tablets, intravenous solutions, and eye gels. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in multiple applications, including CMV retinitis, prevention of CMV infections in organ transplant recipients, and other related conditions.

The ganciclovir market research report is one of a series of new reports from The Business Research Company that provides ganciclovir market statistics, including the ganciclovir industry global market size, regional shares, competitors with the ganciclovir market share, detailed ganciclovir market segments, market trends, and opportunities, and any further data you may need to thrive in the ganciclovir industry. This ganciclovir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ganciclovir market size has grown rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be credited to the rising demand for antiviral therapies, increased adoption of targeted treatments, a growing requirement for effective solutions in transplant patients, heightened attention on chronic viral infections, and improved access to healthcare in developing areas.

The ganciclovir market size is expected to see rapid growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be credited to the increased adoption of antiviral therapies, a rising prevalence of immunocompromised conditions, greater awareness of CMV infections, progress in diagnostic technologies, and the expansion of healthcare infrastructure in emerging markets. Key trends expected during the forecast period include innovations in drug delivery methods, the creation of extended-release formulations, advancements in combination therapies, the use of advanced diagnostic tools for early detection of CMV, and the emergence of personalized treatment strategies for CMV infections.

The increasing incidence of cytomegalovirus (CMV) infections is anticipated to drive the growth of the ganciclovir market in the coming years. CMV infections, caused by a common herpesvirus, can remain latent and reactivate in individuals with weakened immune systems, leading to severe complications such as retinitis, pneumonia, and gastrointestinal disorders-particularly among transplant recipients and individuals with HIV/AIDS. The rise in CMV cases is largely due to the growing population of immunocompromised individuals, whose weakened immune defenses heighten vulnerability to viral reactivation and transmission. Ganciclovir plays a vital role in providing effective antiviral treatment, underlining its importance in managing the increasing CMV infection rates among at-risk populations. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that 1 in 3 children in the U.S. contracts CMV by age 5, and over half of adults are infected by age 40. Furthermore, in October 2022, the National Library of Medicine, a U.S.-based medical institution, noted that approximately 40,000 infants are born each year with congenital CMV (cCMV); of these, around 400 (1%) die from the infection, and nearly 8,000 (25%) suffer long-term complications. Thus, the rising occurrence of CMV infections is contributing to the expansion of the ganciclovir market.

The increase in healthcare expenditure is expected to drive the growth of the ganciclovir market in the future. Healthcare expenditure refers to the total spending on medical services, treatments, and public health by individuals, insurance providers, and governments. This rise in spending is largely attributed to advancements in medical technologies, which often come with high development and implementation costs, necessitate specialized equipment and training, and lead to increased reliance on costly diagnostic and therapeutic procedures. Higher healthcare expenditure facilitates the use of ganciclovir by expanding access to antiviral treatments for managing cytomegalovirus (CMV) infections, particularly among immunocompromised individuals. For example, in May 2024, the Office for National Statistics, a government agency in the UK, reported that the country's healthcare spending in 2024 reached about $421.32 billion (£317 billion), marking a 6.5% rise from 2023. Thus, the growing healthcare expenditure is contributing to the expansion of the ganciclovir market.

In May 2022, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, acquired the rights to Valcyte from Roche Holdings AG for an undisclosed sum. This acquisition expands Cheplapharm's antiviral portfolio, reinforces its position in CMV treatment, and supports its strategy of increasing global access to essential, guideline-recommended medications. Roche Holdings AG, headquartered in Switzerland, is a pharmaceutical company that provides therapies for cytomegalovirus (CMV) infections, including ganciclovir.

Major players in the ganciclovir market are Roche Holding AG, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Fareva Group, Zydus Lifesciences Ltd., Natco Pharma Ltd., Ajanta Pharma Ltd., Micro Labs Ltd., Taj Pharmaceuticals Ltd., Sunways Pvt. Ltd., Accord Healthcare Ltd., AdvaCare Pharma USA, Trifarma S.p.A., Actiza Pharmaceutical Pvt. Ltd., Bakul Group of Companies, Doctor Wonder Healthcare Pvt. Ltd., Sujalam Chemicals, and Aetos Pharma Pvt. Ltd.

North America was the largest region in the ganciclovir market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ganciclovir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ganciclovir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ganciclovir market consists of sales of ganciclovir injectable solutions, ganciclovir capsules, ganciclovir oral solutions, and ganciclovir ophthalmic gels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ganciclovir Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ganciclovir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ganciclovir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ganciclovir market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Injection; Oral
• 2) By Dosage Form: Tablets; Intravenous (IV) Solution; Ophthalmic Gel
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Cytomegalovirus (CMV) Retinitis; Cytomegalovirus (CMV) Prevention In Organ Transplant Patients; Other Viral Applications
• Subsegments:
• 1) By Injection: Lyophilized Powder for Injection; Premixed IV Bags; Intravitreal Injection
• 2) By Oral: Capsules; Oral Solution
• Companies Mentioned: Roche Holding AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ganciclovir Market Characteristics

3. Ganciclovir Market Trends And Strategies

4. Ganciclovir Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ganciclovir Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ganciclovir PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ganciclovir Market Growth Rate Analysis
• 5.4. Global Ganciclovir Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ganciclovir Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ganciclovir Total Addressable Market (TAM)

6. Ganciclovir Market Segmentation

• 6.1. Global Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Oral
• 6.2. Global Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Intravenous (IV) Solution
• Ophthalmic Gel
• 6.3. Global Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Ganciclovir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytomegalovirus (CMV) Retinitis
• Cytomegalovirus (CMV) Prevention In Organ Transplant Patients
• Other Applications
• 6.5. Global Ganciclovir Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lyophilized Powder for Injection
• Premixed IV Bags
• Intravitreal Injection
• 6.6. Global Ganciclovir Market, Sub-Segmentation Of By Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsules
• Oral Solution

7. Ganciclovir Market Regional And Country Analysis

• 7.1. Global Ganciclovir Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ganciclovir Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ganciclovir Market

• 8.1. Asia-Pacific Ganciclovir Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ganciclovir Market

• 9.1. China Ganciclovir Market Overview
• 9.2. China Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ganciclovir Market

• 10.1. India Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ganciclovir Market

• 11.1. Japan Ganciclovir Market Overview
• 11.2. Japan Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ganciclovir Market

• 12.1. Australia Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ganciclovir Market

• 13.1. Indonesia Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ganciclovir Market

• 14.1. South Korea Ganciclovir Market Overview
• 14.2. South Korea Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ganciclovir Market

• 15.1. Western Europe Ganciclovir Market Overview
• 15.2. Western Europe Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ganciclovir Market

• 16.1. UK Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ganciclovir Market

• 17.1. Germany Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ganciclovir Market

• 18.1. France Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ganciclovir Market

• 19.1. Italy Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ganciclovir Market

• 20.1. Spain Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ganciclovir Market

• 21.1. Eastern Europe Ganciclovir Market Overview
• 21.2. Eastern Europe Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ganciclovir Market

• 22.1. Russia Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ganciclovir Market

• 23.1. North America Ganciclovir Market Overview
• 23.2. North America Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ganciclovir Market

• 24.1. USA Ganciclovir Market Overview
• 24.2. USA Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ganciclovir Market

• 25.1. Canada Ganciclovir Market Overview
• 25.2. Canada Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ganciclovir Market

• 26.1. South America Ganciclovir Market Overview
• 26.2. South America Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ganciclovir Market

• 27.1. Brazil Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ganciclovir Market

• 28.1. Middle East Ganciclovir Market Overview
• 28.2. Middle East Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ganciclovir Market

• 29.1. Africa Ganciclovir Market Overview
• 29.2. Africa Ganciclovir Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ganciclovir Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ganciclovir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ganciclovir Market Competitive Landscape And Company Profiles

• 30.1. Ganciclovir Market Competitive Landscape
• 30.2. Ganciclovir Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Ganciclovir Market Other Major And Innovative Companies

• 31.1. Fareva Group
• 31.2. Zydus Lifesciences Ltd.
• 31.3. Natco Pharma Ltd.
• 31.4. Ajanta Pharma Ltd.
• 31.5. Micro Labs Ltd.
• 31.6. Taj Pharmaceuticals Ltd.
• 31.7. Sunways Pvt. Ltd.
• 31.8. Accord Healthcare Ltd.
• 31.9. AdvaCare Pharma USA
• 31.10. Trifarma S.p.A.
• 31.11. Actiza Pharmaceutical Pvt. Ltd.
• 31.12. Bakul Group of Companies
• 31.13. Doctor Wonder Healthcare Pvt. Ltd.
• 31.14. Sujalam Chemicals
• 31.15. Aetos Pharma Pvt. Ltd.

32. Global Ganciclovir Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ganciclovir Market

34. Recent Developments In The Ganciclovir Market

35. Ganciclovir Market High Potential Countries, Segments and Strategies

• 35.1 Ganciclovir Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ganciclovir Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ganciclovir Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer